State of California - Health and Human Services Agency

## **Confidential Case Report of a Birth Defect**

## In a Fetus or Infant Less than One Year of Age

INSTRUCTIONS

- In accordance with State of California law (California Code of Regulations, Title 17, Sections 6531 & 6532), report neural tube defects (NTDs) and/or
  chromosomal abnormalities found in fetuses or infants less than one year of age to the California Genetic Disease Screening Program (GDSP) within 30
  days of initial diagnosis.
- Reportable neural tube defects (NTDs) are outlined by ICD-10-CM Codes Q00.0-Q01.9, Q05.0-Q05.9, Q07.0-Q07.03.
- Reportable chromosomal abnormalities are outlined by ICD-10-CM Codes Q90.0-Q99.9, excluding Q97.3, Q98.3, Q99.1, and Q99.2.
- . Submit a separate form for each individual specimen and for each fetus or infant in a multiple gestation.
- Report the simultaneous occurrence of a neural tube defect and a chromosomal abnormality for the same patient on one single form.
- Print clearly in ink or type using UPPER CASE.
- · Fill bubbles completely when marking.

Genetic Disease Screening Program									

California Department of Public Health

Genetic Disease Screening Program 850 Marina Bay Parkway Room F-175, Mailstop 8200 Richmond, CA 94804

(510) 412-1560 (FAX)

. , ,									
INFORMATION ABOUT THE MOTHER									
1. LAST NAME	2. FI	RST NAME 3. MIDDLE INITIAL							
4. MAIDEN NAME / AKA / OTHER NAMES USED FOR MOTHER	5. PRENATAL ACCESSION NUMBER (if mo	ther participated in the California Prenatal Screening Program)							
		/							
6. DATE OF BIRTH (MM/DD/YYYY)	7. APPROXIMATE AGE AT EDD (if date of birth is unknown)	8. SOCIAL SECURITY NUMBER							
STREET ADDRESS (include apartment number)									
10.CITY	11.STATE	12.ZIP CODE							
13. MOTHER'S RACE / ETHNICITY (mark all that apply)									
O Asian Indian O Chinese O Hawaiiar O Black O Filipino O Hispanic		O White O Other (specify) O Unknown							
O Cambodian O Guamanian O Japanesi		Onknown Other Southeast Asian							
INFORMATION ABOUT THE INFANT									
14.LAST NAME		15. FIRST NAME							
T. DOT WAND		IS. HOT NAME							
16.OTHER NAMES USED FOR INFANT (including father's last nam	ne if known)	17.DATE OF BIRTH (MM/DD/YYYY)							
18. GENDER 19. FETUS LETTER CODE (A, B, C, c)	etc.) 20.BIRTHWEGHT OF INFANT	21.IF DECEASED, DATE OF EXPIRATION (MM/DD/YYYY)							
	grams								
	MATION ABOUT THE REPORTING								
22.LAST NAME (of person completing this form)		23. FIRST NAME (of person completing this form)							
24. DATE FORM COMPLETED (MM/DD/YYYY)	25. TELEPHONE NUMBER (includir	ng extension)							
		- ext							
26. FACILITY TYPE	27. FACILITY NAME A	ND ADDRESS							
O Cytogenetic Laboratory O PDC (please provide PDC code) O Other (specify)									
O Hospital									
O MD									
INFORMATION ABOUT THE PREGNANCY									
28.LMP / LAST MENSTRUAL PERIOD (MM/DD/YYYY)	32. PREGNANCY STATUS	33.DATE OF PREGNANCY STATUS (MM/DD/YYYY)							
	O Continuing Pregnancy								
29.EDD / ESTIMATED DATE OF DELIVERY (MM/DD/YYYY)	34.GESTATIONAL AGE AT TIME OF STATUS								
	/ weeks/days								
30.# OF FETUSES IN PREGNANCY (including fetal demises)	O Selective Reduction O Unknown / Lost to Follow-Up								
	O Other (specify)	35.METHOD USED TO DETERMINE GESTATIONAL AGE							
31.# OF FETUSES IN PREGNANCY WITH A BIRTH DEFECT		OLMP OPhysical Exam							
		OUltrasound							

PRIVACY STATEMENT: The Information Practices Act of 1977 (Civil Code 1798 et. seq.) requires that the following details be provided when a form is used to obtain information from individuals. The data requested in this form are required by the Genetic Disease Screening Program (GDSP) of the California Department of Public Health and are mandated by California Code of Regulations, Title 17, Section 6532. These data are used to provide information to subjects on the prevalence of heural tube defects and chromosomal abnormalities, and to monitor trends of occurrence. These data will also be used to determine the effectiveness of the California Expanded Alpha Fetoprotein (AFP) Screening Program. It is mandatory that health professionals completing this form provide complete and accurate information. The records maintained by the GDSP are confidential, as defined in Civil Code 1798.34, and are exempt from access by any individual, except licensed medical personnel designated by the subject. The information may also be used in special studies, as defined in Health and Safety Code 100330. The furnishing of such information to the Department or its authorized representative or any other cooperating individual, agency, or organization in any such special study shall not subject any person, hospital, or other organization furnishing such information to any actions or damages.

Please list the patient's name in case of page separation:						Genetic Disea	se Scree	ning Program				
INFORMATION ABOUT THE HOSPITAL												
36. NAME OF BIRTH HOSPITAL 38. MOTHER'S MEDICAL RECORD NUMBER												
37.TELEPHONE NUMBER OF BIRTH HOSPITAL			39. INFANT'S ME	EDICAL RECORD	NUMBER							
INFORMATION ABOUT THE PHYSICIAN												
40. NAME AND ADDRESS OF MOTHER'S PHYSICIAN 42. NAME AND ADDRESS OF INFANT'S PHYSICIAN												
41.TELEPHONE NUMBER OF MOTHER'S PHYSICIAN			43. TELEPHONE		IFANT'S PHYSICIAN							
BIRTH DEFECT DIAGNOSIS – CHROMOSOMAL ABNORMALITIES  44. CYTOGENETIC DIAGNOSIS (ISCN Short Form) – Copy and paste or write diagnosis clearly using UPPER CASE below. Include Human Genome Build in nomenclature when applicable.												
Do not report a) Heterochromatin Variants; b) Satellite / Stalk								osaics;				
g) Known Benign Variants; or h) Regions of Homozygosity												
-												
	MEN PREPARATION	50. CLINICAL SIGN		5	33.IS DIAGNOSIS PAR	T OF A SYND	ROME?					
7 21	Cultured Direct				O Yes (specify) O No	· · · · · · · · · · · · · · · · · · ·						
47. CYTOGENETIC LABORATORY SPECIMEN NUMBER		51.INHERITANCE	•	EMENTS	O Unknown							
		O De Novo	Paternal		E4 CAMPLING DATE	(MM/DD \\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\\						
48. NAME OF CYTOGENETIC LABORATORY		I O Congenital Anomalies I										
48. NAIVIE OF CTTOGENETIC LABORATORT												
						D USED TO						
49.CYTOGENETIC SPECIMEN TYPE  O Abortus Specimen O Liveborn Blood O I	Liveborn Tissue	O Dysmorphic Fe		.	AT TIME OF SAMP	LING	O LMP	MINE GA				
O Amniotic Fluid O Liveborn Bone Marrow O	Umbilical Blood (PUBS)	<ul><li>O Maternal Age</li><li>O Other (specify)</li></ul>			/	weeks/ days	O Physic					
	Stillborn Tissue / Blood I		ELIDAL T	IIDE DEEL	ECTS	•	Oillas	lound				
			EURAL I									
57.NEURAL TUBE DEFECT DIAGNOSIS Spina Bifida includes Lipomeningocele, Meningocele,	61. ULTRASOUND INFO		CODE	63.AF-AFP LE	EVEL (in M.o.M.)	1						
Meningomyelocele, and Myelomeningocele					<u></u>							
O Acrania				64.AF-AChE	RESULT							
O Anencephaly O Craniorachischisis	GESTATIONAL AGE AT	TIME OF PROCEDUI	RF	O Positive								
O Encephalocele		weeks/days		O Negative O Not Performed								
O Exencephaly O Injencephaly	ши' ш			65. IF POSTNATALLY DIAGNOSED, WHEN WAS NTD DIAGNOSED?								
O Meckel Gruber	DATE OF PROCEDURE	(MM/DD/YYYY)		O At Time o		<u> </u>						
O Rachischisis		/		O At Time o								
O Spina Bifida / Myelomeningocele - Open O Spina Bifida / Myelomeningocele - Closed	DID ULTRASOUND PRO	DCEDURE DETECT N	TD?	O Other (sp	hysical Examination pecify)							
O Other (specify)	O Yes O No					010 (4444/000)	2000					
	62. AMNIOCENTESIS IN	IFORMATION:		66.DATE OF	POSTNATAL DIAGNO	1515 (IVIIVI/DD/Y	1 ( )					
58.IS HYDROCEPHALY PRESENT?	DF FACILITY OR PDC CODE			/								
O Yes				67.WAS THE	FETAL ABNORMALIT	Y POSTNATAL	LY CON	FIRMED?				
O No	O Yes											
O Unknown 59.IS NTD PART OF A SYNDROME?	TIME OF PROCEDU	RE	O No O Pending									
O Yes (specify)		weeks/days		68. SOURCE(S) OF CONFIRMATION (mark all that apply)								
O No	DATE OF PROCEDURE	(MM/DD/YYYY)		O Autopsy / Pathology Report  O Autopsy / Pathology Report								
O Unknown	/	/		O Clinician	• • •							
60.ARE OTHER ABNORMALITIES PRESENT?	DID AMNIOCENTESIS F	PROCEDURE DETEC	T NTD?		Room Report							
O Yes (specify) O No	O Yes			O Ultrasour	e of Pregnancy nd Report							
O Unknown	O No			O Other (s)								

CDPH 4427 (11/2015) Page 2 of 2